Project Grant R21AI190536
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$481K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $170,000 research project by Prokaryotics Incorporated to develop novel antifungal therapeutics. The goal is to perform structural biology studies on the GPI ethanolamine phosphate transferase enzyme MCD4, which is a promising target for new antifungal drug candidates. The research aims to obtain...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $453,750 to Tufts University School of Medicine to study how certain bacteriophages (viruses that infect bacteria) evade the protective mechanisms of bacteria, including some deadly pathogens like Vibrio cholerae. The project aims to determine the counter-defense mechanisms used by these phages and identify the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,144,714 to the University of Illinois to conduct research aimed at discovering novel antibiotics for gram-negative pathogens. The primary goals are to identify physicochemical traits that allow antibiotics to evade efflux pumps in E. coli, P. aeruginosa, and A. baumannii, and then apply this knowledge to develop at...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is focused on exploring synergistic combinations of aminoglycoside antibiotics to combat multidrug-resistant (MDR) gram-negative bacteria. The $475,036 award, granted on Apr 11, 2025, aims to: 1) Identify dual-aminoglycoside combinations that demonstrate synergistic and maximally suppressive activity against MDR bacterial isolates, while evaluating...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $386,194 to the Massachusetts Institute of Technology (MIT) from July 1, 2025 to June 30, 2027. The funding supports the development of "Molecular Tailoring of Bispecific Antibody-Bottlebrush Conjugates", which aims to create new synthetic methods to access bispecific antibody-bottlebrush conjugate (BSABC)...
This Project Grant award of $407,156.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop new chemical probes to explore the consequences of different complement recruitment strategies for eliminating Gram-negative bacterial pathogens. The key objectives are to: 1) Generate multifunctional compounds that bind to the pathogen Pseudomonas aeruginosa and assess their ability to recruit and kill the bacteria...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $891,678 to the Scripps Research Institute in La Jolla, CA to conduct research on how metabolites from the intestinal microbiota can modulate host immune responses. The researchers will employ chemical biology and proteomics methods to identify specific microbiota-associated bile acid protein targets in mammalian cells...
This $198,630 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to characterize porin mutations and expand the capabilities of the BADLOCK CRISPR-based diagnostic test. The goal is to improve diagnostic capacity for antibiotic-resistant bacterial infections, especially carbapenem-resistant Enterobacterales, in resource-limited settings. Key activities include...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $711,993.00 to Boston Medical Center Corporation to conduct research on the impact of Mycobacterium tuberculosis (MTB) disease on HIV-1 immunity, evolution, and persistence. The research aims to examine how MTB disease affects the development of broadly potent HIV-1 neutralizing antibodies, the emergence of...